Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-1459
    Keywords: Macrophage electrophoresis mobility LAD test ; Multiple sclerosis ; Cellular immunity ; Lymphocyte sensitization ; Linoleic acid effect ; Immunity, cellular
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Mit dem MEM-Test (Field) ist infolge des von sensibilisierten Lymphocyten nach antigener Stimulierung abgegebenen macrophage-slowing-factor (MSF) eine celluläre Immunreaktion feststellbar. Eine Hemmung der Makrophagenmobilität kann bei einer Reihe neurologischer Erkrankungen mit Parenchymdestruktion nachgewiesen werden. Die Modifikation in Form des MEM-LAD (linoleic acid depression)-Testes ergab eine weitere Differenzierung für die untersuchten 146 neurologischen Krankheitsfälle bzw.Normalpersonen: die Reduktion der Mobilitätshemmung für die multiple Sklerose (MS) von durchschnittlich 94,7±4,7% gestattet eine signifikante Unterscheidung zu Normalpersonen mit 55,1±3,7% und anderen neurologischen Krankheiten mit 47,8±7,1%. Die MS-typischen Befunde des MEM-LAD-Testes zeigten innerhalb der verschiedenen Verlaufsformen der MS und bezüglich der Erkrankungsdauer keine wesentlichen Abweichungen, waren auch unabhängig von der immunsuppressiven Therapie. Die pathogenetisch bedeutsamen Ergebnisse des Verfahrens bei Verwandten von MS-Patienten wiesen mit einer zwischen den MS- und Normalwerten stehenden Reduktion (78,5±0,7%) für alle Mütter auf eine familiäre (genetische) Disposition; es wurde dies durch einen gleichartigen Befund bei einem monozygoten Zwilling eines MS-Kranken bestätigt. Die neben den endogenen metabolischen Komponenten für die ätiopathogenetischen Probleme der MS wichtigen exogenen Faktoren können, wie die Ergebnisse bei Kindern ergaben, in einer frühen Lebensphase wirksam sein. In Korrelation zum Prinzip des MEM-LAD-Testes läßt sich aus der suppressiven Wirkung der Linolsäure ein weiteres therapeutisches Konzept ableiten.
    Notes: Summary With the MEM test (Field) one can establish a cellular immune reaction because the sensitized lymphocytes release the macrophage slowing factor (MSF) upon interaction with the appropriate antigen. A macrophage migration inhibition was detected in some neurological diseases with destruction of the parenchyma. The modification MEM-LAD (linoleic acid depression) test made further differentiation possible in the 146 neurological patients and normals. The reduction of macrophage mobility inhibition was 94.7±4.7% in multiple sclerosis (MS) cases as compared with that of normals of 55.1±3.7% and of other neurological diseases of 47.8±7.1%. There were no significant differences due to the course and duration of the disease or to immunosuppressive therapy. The pathogenically important results in relatives of MS patients with values between the MS and normal group (78.5±0.7%) in mothers suggested a familial (genetic) disposition. The same value was found in a monozygotic twin of an MS patient. The results in the children studied showed that besides the endogenic metabolic component the aetiopathogenically important exogenic factors can operate early in life. In correlation with the principle of the MEM-LAD test the suppressive action of linoleic acid can result in a further therapeutic concept.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1534-4681
    Keywords: Melanoma ; Recurrence ; Disease-free interval ; Lymph node dissection
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Although more than 90% of the morbidity and mortality from localized cutaneous melanoma occurs in the first decade after initial surgical treatment, melanoma can recur after a 10-year disease-free interval (DFI) with fatal consequences. We reviewed our melanoma data base of more than 8500 prospectively acquired patients to identify clinicopathological factors that affect the type, rate of occurrence, and outcome of disease recurring 10 years or more after surgical treatment of primary cutaneous melanoma. Methods: From 1971 to 1997, 1907 melanoma patients treated at our cancer center reached or presented with a DFI of 10 years or more after surgical treatment of clinically localized melanoma. Of these, 217 (11%) patients had recurrences (mean DFI, 182 months). The sites of recurrence were local/in-transit in 26 (12%) patients, regional lymph nodes in 101 (47%) patients, and distant sites in 90 (41%) patients. Results: Univariate and multivariate analysis, using patient age and sex, type of initial treatment, and the site, Breslow thickness, and Clark level of the initial tumor, showed that the type of treatment for the primary tumor was a significant (P = .0005) prognostic factor in the development of late nodal recurrence. Of the 217 patients who had recurrences, 172 (79%) had undergone wide local excision for their primary melanoma, and 45 (21%) had undergone wide local excision plus elective lymph node dissection (ELND). The rates of nodal recurrence were 53% (92 of 172) and 20% (9 of 45), respectively, a significant (P = .0001) difference. When all patients with a DFI of 10 years or more were stratified by type of initial treatment, the ELND group demonstrated a significant improvement in disease-free survival and overall survival. Conclusions: The risk of late-recurring nodal disease increases and the chance of long-term survival decreases when wide local excision is performed without ELND. With the advent of sentinel lymphadenectomy, ELND can be selectively performed only for those nodal basins with occult tumor cells, thereby decreasing operative morbidity but allowing identification and early removal of nodal micrometastases.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...